AU2008323676B2 - Methods for administering corticosteroid formulations - Google Patents

Methods for administering corticosteroid formulations Download PDF

Info

Publication number
AU2008323676B2
AU2008323676B2 AU2008323676A AU2008323676A AU2008323676B2 AU 2008323676 B2 AU2008323676 B2 AU 2008323676B2 AU 2008323676 A AU2008323676 A AU 2008323676A AU 2008323676 A AU2008323676 A AU 2008323676A AU 2008323676 B2 AU2008323676 B2 AU 2008323676B2
Authority
AU
Australia
Prior art keywords
corticosteroid
dose
administered
less
budesonide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008323676A
Other languages
English (en)
Other versions
AU2008323676A1 (en
Inventor
Thomas A. Armer
Andrew P. Bosco
Stephen B. Shrewsbury
Paul S. Uster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MAP Pharmaceuticals Inc
Original Assignee
MAP Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAP Pharmaceuticals Inc filed Critical MAP Pharmaceuticals Inc
Publication of AU2008323676A1 publication Critical patent/AU2008323676A1/en
Application granted granted Critical
Publication of AU2008323676B2 publication Critical patent/AU2008323676B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2008323676A 2007-11-09 2008-11-10 Methods for administering corticosteroid formulations Ceased AU2008323676B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US264507P 2007-11-09 2007-11-09
US61/002,645 2007-11-09
US6949808P 2008-03-14 2008-03-14
US61/069,498 2008-03-14
PCT/US2008/083059 WO2009062193A2 (en) 2007-11-09 2008-11-10 Methods for administering corticosteroid formulations

Publications (2)

Publication Number Publication Date
AU2008323676A1 AU2008323676A1 (en) 2009-05-14
AU2008323676B2 true AU2008323676B2 (en) 2014-04-03

Family

ID=40377556

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008323676A Ceased AU2008323676B2 (en) 2007-11-09 2008-11-10 Methods for administering corticosteroid formulations

Country Status (8)

Country Link
US (2) US20090149432A1 (enExample)
EP (1) EP2207527A2 (enExample)
JP (2) JP5537434B2 (enExample)
AU (1) AU2008323676B2 (enExample)
CA (1) CA2705159A1 (enExample)
IL (1) IL205644A0 (enExample)
MX (1) MX2010005100A (enExample)
WO (1) WO2009062193A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2618816A4 (en) * 2010-09-22 2014-10-29 Map Pharmaceuticals Ltd AEROSOL COMPOSITION FOR THE ADMINISTRATION OF MEDICAMENTS
ES2913339T3 (es) * 2014-01-31 2022-06-01 Draka Elevator Products Inc Dispositivo sensor de detección sísmica para equipo de transporte vertical
US20210283145A1 (en) * 2020-03-13 2021-09-16 Softhale Nv Method for the treatment of viral infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW497974B (en) * 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
BRPI0418276B8 (pt) * 2003-12-31 2021-05-25 Cydex Pharmaceuticals Inc formulação líquida inalável compreeendendo budesonida
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Chinese Journal of Experimental & Clinical Virology, June 2007, vol. 21, no. 2, pp. 132-134 *
J South Med Univ, (2007) Vol 27 No 10, pp 1612-1613 *
Journal of Allergy & Clinical Immunology, 1998, vol. 102, no. 5, pp. 789-796 *
'Martindale the complete drug reference,' PHARMACEUTICAL PRESS,(1999) 32nd Edition, pp. 1034-1035. *

Also Published As

Publication number Publication date
US20140323451A1 (en) 2014-10-30
JP2011503109A (ja) 2011-01-27
JP2013227351A (ja) 2013-11-07
AU2008323676A1 (en) 2009-05-14
JP5537434B2 (ja) 2014-07-02
WO2009062193A3 (en) 2009-10-15
EP2207527A2 (en) 2010-07-21
US20090149432A1 (en) 2009-06-11
MX2010005100A (es) 2010-11-12
IL205644A0 (en) 2010-11-30
CA2705159A1 (en) 2009-05-14
WO2009062193A2 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
RU2363449C2 (ru) Водный аэрозольный препарат
US20120067343A1 (en) Aerosol Composition for Administering Drugs
CN1098680C (zh) 适于喷雾的悬浮液制剂及其制备方法
Niemarkt et al. Surfactant for respiratory distress syndrome: new ideas on a familiar drug with innovative applications
AU2010210183B2 (en) Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma
Madney et al. Nebulizers and spacers for aerosol delivery through adult nasal cannula at low oxygen flow rate: an in-vitro study
US7998463B2 (en) Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough, asthma and tussive attacks
US20070193577A1 (en) Disodium cromoglycate compositions and methods for administering same
KR101718372B1 (ko) 에어로졸 볼러스로서의 일로프로스트의 투여
US20130037024A1 (en) Drug and Device Combination System for Flow and Volume Regulated Inhalation and a Method for Treatment of Severe Oral Corticosteroid-Dependent Asthma and Other Respiratory Diseases
US20120040945A1 (en) Use of a Glucocorticoid Composition for the Treatment of Severe and Uncontrolled Asthma
AU2005290312A1 (en) Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks
US20140323451A1 (en) Methods for administering corticosteroid formulations
JP2024502990A (ja) 吸入可能なイマチニブ製剤
Shapiro Once-daily inhaled corticosteroids in children with asthma: nebulisation
Alberts et al. Effect of Aerosol Devices and Administration Techniques on Drug Delivery in a Simulated Spontaneously Breathing Pediatric Tracheostomy Model

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired